544 results about "Polycyclic compound" patented technology

Compounds of formula (I) useful as cancer treatment, the preparation method thereof, pharmaceutical compositions comprising the compounds, and the pharmaceutical uses for the treatment of certain diseases or disorders are disclosed.

The invention relates to a fused ring compound, a preparation method thereof and application of the fused ring compound in medicine. Specifically, the invention relates to a fused ring compound as shown in a general formula (IN), a preparation method thereof, a pharmaceutical composition containing the compound and application of the fused ring compound as a therapeutic agent, in particular to application of the fused ring compound in preparation of drugs for inhibiting KRAS G12D. Wherein each group in the general formula (IN) is as defined in the specification. # imgabs0 #

The invention relates to a fused ring compound, a preparation method thereof and application of the fused ring compound in medicine. Specifically, the invention relates to a fused ring compound as shown in a general formula (IN), a preparation method thereof, a pharmaceutical composition containing the compound and application of the fused ring compound as a therapeutic agent, in particular to application of the fused ring compound in preparation of drugs for inhibiting KRAS G12D. Wherein each group in the general formula (IN) is as defined in the specification. # imgabs0 #

The present disclosure provides a class of compounds represented by formula (I '), or tautomers, stereoisomers or pharmaceutically acceptable salts thereof. The compound disclosed by the invention has a relatively strong agonistic effect on GLP-1R, can be used for treating diseases such as diabetes mellitus, metabolism-related fatty liver diseases, Alzheimer's disease and the like or has an effect of reducing weight. # imgabs0 #

An organic electroluminescence device includes a first electrode, a hole transport region disposed on the first electrode, an emission layer disposed on the hole transport region, an electron transport region disposed on the emission layer, and a second electrode disposed on the electron transport region. The emission layer includes a polycyclic compound represented by Formula 1 to thereby achieve high luminous efficiency:

The invention relates to a pyrimidine-containing polybasic ring derivative inhibitor as well as a preparation method and application thereof. In particular, the invention relates to a pyrimidine-containing multi-element fused ring compound or a stereoisomer thereof, a preparation method thereof, a pharmaceutical composition containing the compound, and an application of the compound or the stereoisomer thereof in preparation of drugs for treating cancers and other related diseases.

The invention belongs to the technical field of OLEDs, and provides a polycyclic compound containing triphenyl silicon and a polyalkyl substituent group and an organic electroluminescent device containing the polycyclic compound. The structural general formula of the polycyclic compound is as shown in formula I in the specification. Benzofuran with higher electronegativity is introduced to a ring structure composed of nitrogen atoms and boron atoms, triphenyl silicon is introduced to the para-position of boron, and the synergistic effect of benzofuran and triphenyl silicon can significantly enhance the multiple resonance of a light-emitting core and reduce vibration relaxation. Due to simultaneous use of the benzofuran and the triphenyl silicon, the problems of vibration relaxation increase, spectrum widening and the like caused by introduction of the polyalkyl substituent are remarkably improved, the luminous efficiency of the material is remarkably improved, and the color purity is improved, so that the requirement of BT.2020 wide color gamut display standard on a luminescent spectrum is met. I

Provided are a compound represented by formula (I'), or a tautomer, stereoisomer or pharmaceutically acceptable salt thereof. The compound represented by formula (I') has a strong agonistic effect on GLP-1R, and can treat diseases such as diabetes, metabolic-associated fatty liver diseases, and Alzheimer's disease, or has a weight loss effect.

Relates to a fused polycyclic compound and a preparation method and pharmaceutical application thereof. The invention provides a compound with a specific general formula, a preparation method of the compound, a pharmaceutical composition comprising the compound, and a pharmaceutical application of the compound in treating related diseases. # imgabs0 #

The invention belongs to the technical field of organic light-emitting materials, and relates to a boron-containing polycyclic compound for an organic light-emitting material. According to the invention, aryl or heteroaryl is taken as a center, 2-3 boron atoms are introduced and form covalent bonds with atoms such as N, O, S and Se, and a rigid polycyclic compound is constructed. The compound provided by the invention is a boron-containing polycyclic compound with multiple resonance effects, can realize narrow-spectrum and high-color-purity luminescence, also has efficient TADF characteristics, and significantly improves the performance of OLED devices. Compared with the prior art, the compound has remarkable advantages in the aspects of molecular structure design, photoelectric property regulation and control, application range and the like, provides important technical support for development of new-generation high-performance OLED materials, and has wide market prospects and application potential.

The invention discloses a polycyclic compound containing a benzene ring as well as a pharmaceutical composition and application thereof. Specifically provided is a compound represented by formula (I-E) or a pharmaceutically acceptable salt thereof. The compound provided by the invention has one or more of the following advantages: (1) the structure is novel; (2) the compound has a good retarding effect on the activity of a NaV1.8 channel; and (3) the method has good selectivity on other subtypes of Nav (such as Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, Nav1.7 and Nav1.9), and is high in safety. # imgabs0 #

The present disclosure relates to a polycyclic compound, a preparation method therefor, and the pharmaceutical use thereof. Specifically, the present disclosure relates to a polycyclic compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a therapeutic agent, in particular, the use as an RAS inhibitor and the use in the preparation of a drug for treating and / or preventing RAS-mediated or dependent diseases or conditions, wherein each group in general formula (I) is as defined in the description.

A light emitting device according to an embodiment includes a first electrode, a hole transport region disposed on the first electrode, an emission layer disposed on the hole transport region, an electron transport region disposed on the emission layer, and a second electrode disposed on the electron transport region. The emission layer includes a fused polycyclic compound represented by Formula 1, which is defined in the specification.

A polycyclic compound represented by formula (1) provides a highly efficient and long-life organic electroluminescent element, wherein at least one of Cy1 and Cy2 has a chemical structure represented by general formula (A1) or (B1). In general formulae (1), (A1), and (B1), R1 to R31, Cy1 to Cy2, L1, L2, and X1 to X3 are completely the same as defined in the description. # imgabs0 #

An organic electroluminescence device includes a first electrode, a second electrode, and an emission layer disposed between the first electrode and the second electrode, wherein the emission layer includes a polycyclic compound represented by Formula 1, thereby showing improved emission efficiency.

Embodiments provide a fused polycyclic compound and a light-emitting element including the fused polycyclic compound. The light emitting element includes a first electrode, a second electrode facing the first electrode, and at least one functional layer disposed between the first electrode and the second electrode, wherein the at least one functional layer includes a first compound represented by Formula 1. Formula 1 explained in the description: # imgabs0 # [Formula 1]

The present invention relates to an organic light-emitting device employing, as a host of a light emission layer, an anthracene derivative compound having a characteristic structure by introduction of a benzofuran structure into the anthracene backbone, and as a dopant of the light emission layer, a polycyclic compound having a characteristic structure. The organic light-emitting device according to the present invention is an organic light-emitting device with significantly improved external quantum efficiency and can be advantageously utilized not only for lighting devices but also for various display devices, such as flat, flexible, and wearable displays.

Provided are a light-emitting element, a polycyclic compound, and a display device. The light-emitting element includes a first electrode, a second electrode disposed on the first electrode, and an emission layer disposed between the first electrode and the second electrode. The emission layer may include a polycyclic compound including a core structure having an N atom and a B atom, two terphenyl groups bonded to the core structure, a polyring connecting the two terphenyl groups, and a substituent having a large steric hindrance, such that the polycyclic compound has a spherical structure in three dimensions. The shape of the polycyclic compound can reduce aggregation and / or interaction among molecules of the polycyclic compound.

The invention provides a compound as shown in a formula (I), and a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. As a GLP-1R agonist, the compound and the pharmaceutical composition thereof can be used for preparing drugs for treating and / or preventing diseases mediated by GLP-1R. # imgabs0 #

The invention discloses a polycyclic compound containing a benzene ring as well as a pharmaceutical composition and application thereof. Specifically provided is a compound represented by formula (I-C) or a pharmaceutically acceptable salt thereof. The compound provided by the invention has one or more of the following advantages: (1) the structure is novel; (2) the compound has a good retarding effect on the activity of a NaV1.8 channel; and (3) the method has good selectivity on other subtypes of Nav (such as Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, Nav1.7 and Nav1.9), and is high in safety. # imgabs0 #

The present disclosure relates to dihydropyrimidine-2, 4 (1H, 3H) -dione-containing polycyclic compounds, or pharmaceutically acceptable salts thereof, and compositions thereof which are effective to reduce or modulate widely interspaced zinc finger motifs (WIZ) protein expression levels and / or induce fetal hemoglobin (HbF) expression, and also relates to methods of their preparation and their use in treatment of subjects in need.

The present invention relates to a polycyclic compound having a characteristic fused ring structure represented by the following [Formula 1], and a high-efficiency and long-lifetime organic electroluminescent device having excellent luminous efficiency and significantly improved lifetime and the like by employing the same in a light emitting layer in the organic electroluminescent device.

An organic electroluminescence device includes: a first electrode; a second electrode disposed on the first electrode; and at least one organic layer disposed between the first electrode and the second electrode. wherein the at least one organic layer includes a polycyclic compound having a core structure including a n,n′-bicarbazole moiety and, outside the core structure, at least one optionally substituted carbazole group, and the substituted or unsubstituted carbazole groups of the core structure substituted at any one among carbon atoms at position n±1 of the n,n′-bicarbazole moiety, and any one among carbon atoms at position n′±1 of the n,n′-bicarbazole moiety, respectively; and n and n′ are, independently from one another, integers of 1 to 4 (where n±1 and n′±1 are not 0).

A substituted polycyclic compound having biological inhibitory activity represented by formula (II), a preparation method therefor, and a use thereof. The use comprises a use of the compound of formula (II) in the preparation of a drug for treating MLL-related diseases. In the preparation process, the compound is obtained by means of a series of reactions such as substitution, cyclization, reduction, and deprotection.

The invention relates to a method for semi-solid-phase synthesis of a polycyclic compound and an intermediate, a long chain is synthesized through solid phase, then two-step ring closing is performed to form a key intermediate, and simple derivation is performed on the basis of the key intermediate to obtain a PCSK9 antagonist compound. According to the invention, starting materials for solid-phase synthesis are selected, steric hindrance is effectively avoided, and solid-phase reaction and subsequent liquid-phase correlation cyclization can be smoothly carried out, so that the yield is improved, and the cost is reduced.

A light emitting device of an embodiment includes a first electrode, a second electrode on the first electrode, and an emission layer between the first electrode and the second electrode and including a fused polycyclic compound represented by Formula 1. Accordingly, the light emitting device of an embodiment may show a low driving voltage, high efficiency and long-life characteristics.

A light-emitting element including a first electrode, a second electrode provided on the first electrode, and an emission layer provided between the first electrode and the second electrode is provided. The emission layer may include a polycyclic compound having N atoms and a B, two terphenyl groups bonded to a polycyclic ring, and a sterically bulky substituent such that the polycyclic compound has a sphere-like structure in three dimensions. The shape of the polycyclic compound may reduce aggregations, interactions, and / or the like between molecules of the polycyclic compound.

The present invention relates to an anthracene derivative compound having a characteristic structure in which an aryl group is introduced into a skeletal structure in which deuterium-substituted phenyl and anthracene are linked. In addition, the present invention relates to a high-efficiency, long-life organic light-emitting device of which the luminous efficiency and lifetime characteristics are significantly improved by employing a polycyclic compound having a characteristic structure as a dopant for a light-emitting layer while employing said compound as a host for the light-emitting layer. Furthermore, the present invention relates to a high-efficiency, long-life organic light-emitting device of which the luminous efficiency and lifetime characteristics are significantly improved by employing a polycyclic compound having a characteristic structure as a dopant for a light-emitting layer while forming a host of the light-emitting layer with a plurality of materials of one or more characteristic anthracene compounds in addition to said compound.

The invention relates to a synthesis method of a polycyclic compound and an intermediate, a long chain is synthesized firstly, then two-step ring closing is performed to form a key intermediate, and simple derivation is performed on the basis of the key intermediate to obtain a PCSK9 antagonist compound. According to the invention, a ring closing route and an intermediate are optimized, and the ring closing yield is improved.